ERBB2 and inflammatory breast carcinoma: COX-2 (cyclooxygenase-2) has been demonstrated to be upregulated in IBC, known to moderate the production of estrogen and interact with both HER1 and HER2, driving invasion and migration in the stem-cell-like population of cancer, making it a possible therapeutic target.